Pimavanserin

Pimavanserin

Clinical data
Trade names	Nuplazid
Other names	ACP-103; BVF-036; BVF-048
License data	US DailyMed: Pimavanserin
Routes of administration	By mouth
ATC code	N05AX17 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	94–97%
Metabolism	Hepatic (CYP3A4, CYP3A5, CYP2J2)
Elimination half-life	54–56 hours
Identifiers
IUPAC name N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide
CAS Number	706779-91-1 Y 706782-28-7 (tartrate)
PubChem CID	10071196
DrugBank	DB05316 N
ChemSpider	8246736 N
UNII	JZ963P0DIK
KEGG	D08969 N
ChEBI	CHEBI:133017 N
ChEMBL	ChEMBL2111101 N
CompTox Dashboard (EPA)	DTXSID90990906
Chemical and physical data
Formula	C25H34FN3O2
Molar mass	427.564 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)COc3ccc(cc3)CNC(=O)N(C(CC2)CCN2C)Cc(cc1)ccc1F
InChI InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30) N Key:RKEWSXXUOLRFBX-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis and is also being studied for the treatment of Alzheimer’s disease psychosis, schizophrenia, agitation, and major depressive disorder. Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist.

Pharmacology

Pharmacodynamics

Pimavanserin acts as an inverse agonist and antagonist at serotonin 5-HT_2A receptors with high binding affinity (K_i 0.087 nM) and at serotonin 5-HT_2C receptors with lower binding affinity (K_i 0.44 nM). Pimavanserin shows low binding to σ₁ receptors (K_i 120 nM) and has no appreciable affinity (K_i >300 nM) to serotonin 5-HT_2B, dopamine (including D₂), muscarinic acetylcholine, histamine, or adrenergic receptors, or to calcium channels.

Pimavanserin has a unique mechanism of action relative to other antipsychotics, behaving as a selective inverse agonist of the serotonin 5-HT_2A receptor, with 40-fold selectivity for this site over the 5-HT_2C receptor and no significant affinity or activity at the 5-HT_2B receptor or dopamine receptors.

History

Development

Pimavanserin was developed by Acadia Pharmaceuticals.

Pimavanserin is expected to improve the effectiveness and side effect profile of antipsychotics. The results of a clinical trial examining the efficacy, tolerability and safety of adjunctive pimavanserin to risperidone and haloperidol were published in November 2012, and the results showed that pimavanserin potentiated the antipsychotic effects of subtherapeutic doses of risperidone and improved the tolerability of haloperidol treatment by reducing the incidence of extrapyramidal symptoms.

The drug met expectations for a Phase III clinical trial for the treatment of Parkinson's disease psychosis, and has completed Phase II trials for adjunctive treatment of schizophrenia alongside an antipsychotic medication.

In September 2014, the United States Food and Drug Administration (FDA) granted breakthrough therapy status to Acadia's New Drug Application for pimavanserin.

FDA Approval

In April 2016, Nuplazid (pimavanserin) was approved by the FDA for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The non-binding advisory panel recommendation of 12-to-2 in support of approval that preceded the FDA approval action noted that the drug met an important need, despite its only providing modest benefits and posing serious safety issues.

In June 2018, the FDA approved new dosages of pimavanserin to treat hallucinations and delusions associated with Parkinson’s disease psychosis. A 34 mg capsule and 10 mg tablet formulation were approved. Previously, patients were required to take two 17 mg tablets to achieve the recommenced 34 mg dose per day. The 10 mg dose is indicated for patients also taking CYP3A4 inhibitors (eg. ketoconazole).

HARMONY-Trial

In a phase III, double-blind, randomized, placebo-controlled trial (ClinicalTrials.gov number NTC03325556) pimavanserin was applicated in patients with dementia-related psychosis. The dementia was caused by Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia, Parkinson's disease with dementia, or vascular dementia. The trial was stopped early for efficacy. Patients treated with pimavanserin had a relapse in 13%, without in 28% (hazard ratio 0.35; 95% CI = 0.17-0.73; p = 0.005). Longer and larger trials are suggested.

Controversy

In April 2018, CNN reported that some in the FDA were concerned that pimavanserin (Nuplazid) was "risky" when it was approved and noted there have been a substantial number of deaths reported by those using the drug. The story further noted that the drug was approved based on a "six-week study of about 200 patients". The FDA began post-market monitoring of the drug to assess the validity of these claims. In September 2018, the FDA stated their review "did not identify any new or unexpected safety findings with Nuplazid, or findings that are inconsistent with the established safety profile currently described in the drug label".

Research

Pimavanserin is under development for the treatment of major depressive disorder, schizophrenia, agitation, and psychiatric disorders. As of March 2022, pimavanserin is in phase 3 clinical trials for major depressive disorder and schizophrenia, phase 2 trials for agitation, and phase 1 trials for psychiatric disorders. It was also under development for the treatment of insomnia, drug-induced akathisia, and drug-induced dyskinesia, but development for these indications was discontinued.